Since an neuroprotective influence of IGF-I has been described [41], systemic administration of IGF-I has already been used in therapeutic trials in neurodegenerative and muscle atrophy associated diseases such as amyotrophic lateral sclerosis patients [24–26] and recently in older adults [52, 53]. Here, IGF1 is linked to amyotrophic lateral sclerosis.